Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $164.5 million.

  • Ascendis Pharma A's Receivables - Net fell 740.26% to $164.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $164.5 million, marking a year-over-year decrease of 740.26%. This contributed to the annual value of $159.7 million for FY2025, which is 1011.07% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Receivables - Net is $164.5 million, which was down 740.26% from $157.5 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Receivables - Net ranged from a high of $177.7 million in Q4 2024 and a low of $72374.2 during Q1 2021
  • Moreover, its 5-year median value for Receivables - Net was $25.6 million (2023), whereas its average is $48.5 million.
  • In the last 5 years, Ascendis Pharma A's Receivables - Net plummeted by 8023.09% in 2021 and then surged by 890671.85% in 2022.
  • Over the past 5 years, Ascendis Pharma A's Receivables - Net (Quarter) stood at $2.5 million in 2021, then surged by 382.81% to $12.2 million in 2022, then skyrocketed by 217.65% to $38.6 million in 2023, then soared by 360.35% to $177.7 million in 2024, then dropped by 7.4% to $164.5 million in 2025.
  • Its last three reported values are $164.5 million in Q4 2025, $157.5 million for Q3 2025, and $125.0 million during Q2 2025.